- Poster presentation
- Open Access
Pharmacokinetics of meropenem during continuous renal replacement therapy in critically ill patients
Critical Care volume 18, Article number: P403 (2014)
Antibiotic dosing for patients with acute renal failure receiving continuous renal replacement therapy (CRRT) is a clinical challenge. The aim of this study was to investigate the pharmacokinetics of meropenem (M) during CRRT.
A prospective and multicenter study was conducted at seven hospitals. Fifteen critically ill patients undergoing either continuous venovenous hemofiltration (CVVHF) or hemodiafiltration (CVVHDF) were included. Serum and ultrafiltrate (UF) levels of M were determined by liquid chromatography. Blood samples were drawn 24 hours after starting CRRT at 08:00 a.m., 09:00 a.m., 10:00 a.m., 01:00 p.m., 06:00 p.m., 20:00 p.m. and 08:00 a.m. of the following day. CRRT clearance (Cl), total amount of M in the UF (MUF), percentage of the dose extracted by CRRT (EF) and the AUC (ng/hour/ml) were calculated.
Nine patients were treated with CVVHDF and six with CVVHF. M (0.5 to 2 g) was administered every 6 to 12 h by i.v. infusion over 15 minutes. Data (mean and SD) concerning the dialysate flow rate (DF; ml/hour), blood flow rate (ml/minute) and the average UF rate (ml/ kg/hour) for CRRT techniques are shown in Table 1. Pharmacokinetic parameters for M are depicted in Table 2. No differences in either EF or M Cl between the two CRRT techniques were observed.
A significant removal of M by CVVHF/CVVHDF was observed. Dose adjustment is necessary in critically ill patients receiving CRRT.
Supported by EC 81/00469.
About this article
Cite this article
Solé Violan, J., Ferrer Agüero, J., Sádaba, B. et al. Pharmacokinetics of meropenem during continuous renal replacement therapy in critically ill patients. Crit Care 18, P403 (2014). https://doi.org/10.1186/cc13593
- Renal Failure
- Emergency Medicine
- Multicenter Study
- Pharmacokinetic Parameter
- Acute Renal Failure